Table 3

Changes in body composition and bone mineral density between 3 and 24 months

P value


Treatment A (n = 14)

Treatment B (n = 11)

Time

Treatment × Compliance × Time


Body mass index (kg/m2)

0.54 (-0.37 to 1.44)

0.89 (-0.13 to 1.91)

0.07

0.37

Fat mass (kg)

0.36 (-1.54 to 2.25)

3.77 (1.63 to 5.90)

0.028

0.040

Fat mass index (kg/m2)

0.05 (-0.62 to 0.72)

1.24 (0.48 to 2.00)

0.035

0.035

Fat (%)

0.15 (-2.03 to 1.73)

2.80 (0.67 to 4.91)

0.11

0.17

Trunk/peripheral fat ratio

0.15 (-0.05 to 0.36)

0.18 (-0.05 to 0.42)

0.18

0.82

Trunk fat (kg)

-0.01 (-1.26 to 1.25)

1.11 (-1.95 to 4.17)

0.40

0.36

Lean body mass (kg)

1.12 (-0.06 to 2.30)

0.52 (-0.81 to 1.86)

0.007

0.79

Appendicular lean mass (kg)

0.08 (-0.65 to 0.80)

0.25 (-0.56 to 1.07)

0.26

0.83

Fat-free mass

1.23 (0.08 to 2.38)

0.57 (-0.73 to 1.87)

0.004

0.69

Fat-free mass index

0.29 (-0.15 to 0.72)

0.16 (-0.33 to 0.65)

0.011

0.63

L2 to L4

BMD (g/cm2)

0.02 (-0.01 to 0.05)

0.03(0.00 to 0.06)

0.15

0.56

Z score

0.31 (0.06 to 0.57)

0.29 (0.00 to 0.58)

0.030

0.26

T score

0.26 (-0.03 to 0.55)

0.26 (-0.03 to 0.55)

0.20

0.55

BMD (g/cm2)

0.00 (-0.02 to 0.02)

0.01 (-0.03 to 0.01)

0.19

0.63

Z score

0.12 (-0.06 to 0.30)

0.04 (-0.24 to 0.17)

0.24

0.63

T score

0.01 (-0.14 to 0.17)

0.12 (-0.29 to 0.06)

0.20

0.32


Changes in body composition and bone mineral density (BMD) between 3 and 24 months, using a mixed linear model. Data presented as mean (95% confidence interval). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. Changes between 3 and 12 months and patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant.

Engvall et al. Arthritis Research & Therapy 2010 12:R197   doi:10.1186/ar3169

Open Data